Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug discovery.

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

The once-popular genetic testing company will be acquired by Regeneron after filing for bankruptcy, but the questions about ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron plans to buy 23andMe out of bankruptcy for $256 million, potentially bringing to a close the saga of the consumer ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business ...

Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million and plans to continue consumer DNA testing services without interruption.

23andMe has found a buyer in biotech company Regeneron Pharmaceuticals. Its business floundered after a data hack, lawsuit, and tumbling stock prices. For those concerned about their dataset ...

Once the hottest start-up in Silicon Valley, shares for the San Francisco-based company soared as much as 158% on Thursday. Investors see the sensitive data of 23andMe’s 15 million customers as ...